Recombinant Human Anti-HCV E2 Antibody (HC84-1)
CAT#: PABL-120
Recombinant Human Antibody (HC84-1) is capable of binding to a highly conserved region on the E2 glycoprotein encompassing aa 412 to 423, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HCV E2 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HCV E2 mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
Published Data
Figure 1 Crystal structure of the epitope II peptide from the complex with HC84-1 (A) and the complex with HC84-27 (D) is shown as cartoon displaying the side chains as sticks. View on the side of the peptide facing the paratope. Residues W437-F442 make a 1.5 α-helical turn followed by an extended segment containing residues Y443-K446.
Krey, T., Meola, A., Keck, Z. Y., Damier-Piolle, L., Foung, S. K., & Rey, F. A. (2013). Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS pathogens, 9(5), e1003364.
![Figure 2 (A) Dose-dependent neutralization of 1a H77 HCVcc and (B) 2a JFH1 HCVcc, as determined by FFU reduction assay [27], [43]. The antibodies are ordered from the lowest to the highest concentration required to reach 50% maximal neutralization concentration (IC50), as summarized in Table 1. Infectious 1a H77C (HJ3–5) chimeric virus or 2a JFH1 inoculum was incubated with each HMAb, at concentrations ranging from 0.005–20 µg/ml against 1a H77C and from 0.0005–20 µg/ml against 2a JFH1, prior to inoculation onto Huh7.5 cells that were pre-seeded in eight-well tissue culture chamber slides. Cells were fixed and immunostained with a MAb to NS3 antigen at day 4 p.i., and enumerated by FFU-reduction assay.](https://img.creativebiolabs.net/productimages/PABL-120-2.png)
Figure 2 (A) Dose-dependent neutralization of 1a H77 HCVcc and (B) 2a JFH1 HCVcc, as determined by FFU reduction assay [27], [43]. The antibodies are ordered from the lowest to the highest concentration required to reach 50% maximal neutralization concentration (IC50), as summarized in Table 1. Infectious 1a H77C (HJ3–5) chimeric virus or 2a JFH1 inoculum was incubated with each HMAb, at concentrations ranging from 0.005–20 µg/ml against 1a H77C and from 0.0005–20 µg/ml against 2a JFH1, prior to inoculation onto Huh7.5 cells that were pre-seeded in eight-well tissue culture chamber slides. Cells were fixed and immunostained with a MAb to NS3 antigen at day 4 p.i., and enumerated by FFU-reduction assay.
Keck, Z. Y., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J.,... & Bukh, J. (2012). Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.PLoS pathogens, 8(4), e1002653.
Figure 3 (D) Dose-dependent neutralization of JFH1-based genotypes 1–5 C-NS2 recombinant viruses by HMAb HC-84.1 were determined by FFU reduction assay. IC50 values for each respective antibody against different genotype HCVcc are as indicated.
Keck, Z. Y., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J.,... & Bukh, J. (2012). Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.PLoS pathogens, 8(4), e1002653.
Figure 4 (A) Antibody binding to H77C (wt) and D535A recombinant E2 lysates by ELISA. The assays were performed with 1 µg of E2/ml that was captured by GNA pre-coated wells, and followed by incubation with each HMAb at 1 µg/ml (x-axis). Positive control is HC-1, an antigenic domain B HMAb and negative control is R04. The y-axis shows the mean optical density (O.D.) values.
Keck, Z. Y., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J.,... & Bukh, J. (2012). Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.PLoS pathogens, 8(4), e1002653.
Figure 5 (B) Immunoprecipitation of 1a H77C recombinant E1E2 lysate by each HCV-84 HMAb (as indicated at the top of the panel). HC-1, an antigenic domain B HMAb, was used as a positive control and R04 was used as a negative control. The immunoprecipitated pellet was separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis under reducing conditions, and immunoblots were analyzed with HMAbs recognizing linear epitopes: anti-E2, HC-33.1 and anti-E1, H-111.
Keck, Z. Y., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J.,... & Bukh, J. (2012). Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.PLoS pathogens, 8(4), e1002653.
Figure 6 (C) HC-84 HMAbs do not bind to denatured 1a HCV E2. Recombinant E1E2 lysate was either left untreated (black bars) or denatured by incubation with 0.5% sodium dodecyl sulfate and 5 mM dithiothreitol for 15 min at 56°C (red bars). After treatment, the proteins were diluted 1∶5 in BLOTTO and captured by pre-coated GNA wells. After washing and blocking, bound proteins were incubated with each HC-84 HMAb at 5 µg/ml (x-axis) and a control HMAb, HC-33.1. Bound antibody was detected as described in Materials and Methods. The y-axis shows the mean optical density values for triplicate wells.
Keck, Z. Y., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J.,... & Bukh, J. (2012). Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.PLoS pathogens, 8(4), e1002653.
![Figure 7 (A) Dual antibody immunofluorescence staining of Huh7.5 cells infected with JFH1 2a virus after multiple rounds of neutralization by the respective antibody. R04, a human monoclonal antibody against CMV was used as mock selection. HCV E2 glycoprotein was stained with the respective antibody under which viral escape mutants were selected (green). Total virus infected cells were stained with anti-NS3 antibody labeled with Alexa-594 (red). The cells were counterstained with Hoechst nuclear stain H33342 (blue). Escape mutants were assessed for CBH-2 (a neutralizing domain B HMAb [43]) at passage 3 in 10 µg/ml, HC-84.1 at passage 4 in 0.5 µg/ml](https://img.creativebiolabs.net/productimages/PABL-120-7.png)
Figure 7 (A) Dual antibody immunofluorescence staining of Huh7.5 cells infected with JFH1 2a virus after multiple rounds of neutralization by the respective antibody. R04, a human monoclonal antibody against CMV was used as mock selection. HCV E2 glycoprotein was stained with the respective antibody under which viral escape mutants were selected (green). Total virus infected cells were stained with anti-NS3 antibody labeled with Alexa-594 (red). The cells were counterstained with Hoechst nuclear stain H33342 (blue). Escape mutants were assessed for CBH-2 (a neutralizing domain B HMAb [43]) at passage 3 in 10 µg/ml, HC-84.1 at passage 4 in 0.5 µg/ml
Keck, Z. Y., Xia, J., Wang, Y., Wang, W., Krey, T., Prentoe, J.,... & Bukh, J. (2012). Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.PLoS pathogens, 8(4), e1002653.
❮
![Figure 2 (A) Dose-dependent neutralization of 1a H77 HCVcc and (B) 2a JFH1 HCVcc, as determined by FFU reduction assay [27], [43]. The antibodies are ordered from the lowest to the highest concentration required to reach 50% maximal neutralization concentration (IC50), as summarized in Table 1. Infectious 1a H77C (HJ3–5) chimeric virus or 2a JFH1 inoculum was incubated with each HMAb, at concentrations ranging from 0.005–20 µg/ml against 1a H77C and from 0.0005–20 µg/ml against 2a JFH1, prior to inoculation onto Huh7.5 cells that were pre-seeded in eight-well tissue culture chamber slides. Cells were fixed and immunostained with a MAb to NS3 antigen at day 4 p.i., and enumerated by FFU-reduction assay.](https://img.creativebiolabs.net/productimages/PABL-120-2.webp)
![Figure 7 (A) Dual antibody immunofluorescence staining of Huh7.5 cells infected with JFH1 2a virus after multiple rounds of neutralization by the respective antibody. R04, a human monoclonal antibody against CMV was used as mock selection. HCV E2 glycoprotein was stained with the respective antibody under which viral escape mutants were selected (green). Total virus infected cells were stained with anti-NS3 antibody labeled with Alexa-594 (red). The cells were counterstained with Hoechst nuclear stain H33342 (blue). Escape mutants were assessed for CBH-2 (a neutralizing domain B HMAb [43]) at passage 3 in 10 µg/ml, HC-84.1 at passage 4 in 0.5 µg/ml](https://img.creativebiolabs.net/productimages/PABL-120-7.webp)
❯
Specifications
- Immunogen
- Hepatitis C virus E2 envelope protein
- Host Species
- Human
- Derivation
- Human
- Type
- IgG
- Specificity
- Tested positive against native HCV E2
- Species Reactivity
- HCV
- Clone
- HC84-1
- Applications
- WB, ELISA, Neut, FuncS, IP, IF
Product Property
- Purity
- >95% by SDS-PAGE and HPLC analysis
- Storage
- Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
Applications
- Application Notes
- The antibody was validated for ELISA, IP, IF and Neut. For details, refer to published data.
Target
- Alternative Names
- E2; HCV; envelope protein; hepatitis C virus
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for PABL-120. Click the button above to contact us or submit your feedback about this product.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "Clone HC84-1"
- CAT
- Product Name
See other products for "E2"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABL-040 | Recombinant Mouse Anti-CHIKV E2 glycoprotein Antibody (PABL-040) | IF, Neut, IP | IgG |
| PABL-505 | Recombinant Rat Anti-HCV E2 antigenic region 412-423 Antibody (311) | Neut | IgG |
| PABC-184 | Recombinant Chimeric (Human/Mouse) Anti-HCV glycoprotein E2 Antibody (mAb1:7) | Neut | IgG |
| HPAB-N0074-YC | Recombinant Humanized Anti-E2 Antibody (TRN-1008) | Neut, ELISA, WB | Humanized IgG |
| HPAB-N0075-YC | Recombinant Human Anti-E2 Antibody (TRN-1007) | Neut, ELISA, WB | Human IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PSBL-118 | Recombinant Rat Anti-HCV E2 Antibody scFv Fragment (3/11) | WB, ELISA, Neut, FuncS | scFv |
| PSBL-119 | Recombinant Human Anti-HCV E2 Antibody scFv Fragment (HC33.1) | Neut, FuncS | scFv |
| PSBL-120 | Recombinant Human Anti-HCV E2 Antibody scFv Fragment (HC84-1) | WB, ELISA, Neut, FuncS | scFv |
| PSBL-121 | Recombinant Mouse Anti-HCV E2 Antibody scFv Fragment (HC84-27) | Neut, FuncS | scFv |
| PFBC-184 | Recombinant Chimeric (Human/Mouse) Anti-HCV glycoprotein E2 Antibody Fab Fragment (mAb1:7) | Neut | Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PFBL-040 | Recombinant Mouse Anti-CHIKV E2 glycoprotein Antibody Fab Fragment (PFBL-040) | Neut, FuncS | Fab |
| PFBL-357 | Recombinant Human Anti-VEEV E2 Antibody Fab Fragment (F5) | WB, ELISA, Neut, FuncS | Fab |
| PFBL-462 | Recombinant Mouse Anti-Epitope II of HCV E2 Antibody Fab Fragment (mAb 12) | WB, FuncS | Fab |
| PFBL-502 | Recombinant Rat Anti-HCV E2 antigenic region 412-423 Antibody Fab Fragment (311) | Neut | Fab |
| PSBC-184 | Recombinant Chimeric (Human/Mouse) Anti-HCV glycoprotein E2 Antibody scFv Fragment (mAb1:7) | Neut | scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PNBL-019 | Recombinant Anti-HCV E2 VHH Single Domain Antibody (PNBL-019) | Inhib, FuncS | Llama VHH |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-238CT | Anti-HCV E2 Recombinant Antibody (Y47F) | ELISA, WB | Human antibody |
| TAB-238CT-S(P) | Anti-HCV E2 Recombinant Antibody scFv Fragment (Y47F) | ELISA, WB | Human antibody |
| TAB-239CT-S(P) | Anti-HCV E2 Recombinant Antibody scFv Fragment (Y47W) | ELISA, WB | Human antibody |
| TAB-238CT-F(E) | Anti-HCV E2 Recombinant Antibody Fab Fragment (Y47F) | ELISA, WB | Human antibody |
| TAB-239CT-F(E) | Anti-HCV E2 Recombinant Antibody Fab Fragment (Y47W) | ELISA, WB | Human antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MHC-YF094 | DRB1*03:01/HPV E2 (PIVQLQGDSNCLKCFR) MHC Monomer | MHC Multimer | |
| MHC-YF095 | DRB1*03:01/HPV E2 (MEAIAKRLDACQDQLLELYE) MHC Monomer | MHC Multimer | |
| MHC-YF1028 | APC-DRB1*03:01/Human E2 (MEAIAKRLDACQDQLLELYE) MHC Tetramer | FCM | |
| MHC-YF1041 | APC-DRB1*03:01/Human E2 (PIVQLQGDSNCLKCFR) MHC Tetramer | FCM | |
| MHC-YF1180 | PE-DRB1*03:01/Human E2 (MEAIAKRLDACQDQLLELYE) MHC Tetramer | FCM |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: Inhib, Cyt
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, ELISA, FuncS
Application: WB, ELISA, FC, IHC, IP
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, Vaccine, FuncS
Application: IF, ICC, WB, IHC-P, IP
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
